Irritable Bowel Syndrome News

CHICAGO — Patients with diarrhea-predominant irritable bowel syndrome treated with eluxadoline experienced greater rates of relief, compared with patients who received placebo, a researcher said during a late-breaking presentation at Digestive Disease Week.

Screening for celiac disease in pediatric primary was warranted for patients with irritable bowel syndrome but not for children with other functional gastrointestinal disorders, according to new research.

A genetic component for increased risk for irritable bowel syndrome was observed among first- second- and third-degree relatives along with an increased non-genetic risk factor among spouses, according to a nationwide family study in Sweden.

Analysis of volatile organic compounds emitted from stool samples distinguished patients with either inflammatory bowel disease or irritable bowel syndrome, according to new data from researchers in the UK.

Non-biomedical factors exerted a stronger effect on the self-reported health of patients with irritable bowel syndrome than disease symptoms themselves, according to new data.

Patients with chronic constipation, with or without irritable bowel syndrome, tended to present without pain, but those who experienced pain were generally younger, more constipated, and more symptomatic than those without pain in a recent study.

Patients with irritable bowel syndrome and visceral hypersensitivity to rectal distension showed increased pain perception and anxiety response when capsaicin was applied to rectal mucosa in a recent study.

Avoiding foods that included fermentable oligosaccharides, disaccharides, monosaccharides and polyols significantly reduced irritable bowel syndrome symptoms, researchers have determined.

Top-line results from a phase 2 study of Lexicon Pharmaceuticals LX1033 drug candidate for the treatment of diarrhea-predominant irritable bowel syndrome did not meet the primary endpoint, a company news release said.

Soligenix has initiated a randomized, double blind, placebo-controlled phase 2 trial for orBec, its potential treatment for gastrointestinal manifestations of chronic graft-versus-host disease, a company news release said.